Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{166614,
        author = {P.Sree vidya and D.Sailaja and B.Manasa and O.Ravindra babu and M.Surya Prakash},
        title = {Review on pulmonary devices, Respiratory disorders and Management},
        journal = {International Journal of Innovative Research in Technology},
        year = {2024},
        volume = {11},
        number = {2},
        pages = {1690-1696},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=166614},
        abstract = {Pulmonary drug delivery systems represent a pivotal advancement in the treatment of respiratory diseases, offering direct medication administration to the lungs for conditions such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. These systems provide several advantages, including rapid onset of action, local targeting with high drug concentrations, and reduced systemic side effects. The primary types of pulmonary delivery devices include metered dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers, each with unique mechanisms and specific use cases. Emerging technologies, such as smart inhalers and nanoparticle-based systems, are enhancing delivery efficacy and patient adherence. Key considerations for effective pulmonary drug delivery involve optimizing particle size for deep lung deposition, ensuring formulation stability, and designing user-friendly devices. With ongoing research and technological advancements, pulmonary drug delivery continues to improve therapeutic outcomes and patient quality of life in respiratory disease management.},
        keywords = {Nanotechnology, pulmonary diseases, pulmonary devices, pulmonary drug delivery.},
        month = {July},
        }